• Asalyxa Bio

  Participated · Seed · Feb 2021

  Asalyxa Bio develops nano-engineered, immune cell-targeted therapeutics built on its proprietary PANTHER technology platform. The PANTHER platform enables targeted delivery of therapeutic compounds directly to neutrophils and other key immune cells, and can deliver existing and novel drugs. Its lead program, ASX-100, is a neutrophil-targeted formulation being developed for the resolution of Acute Respiratory Distress Syndrome (ARDS). Proceeds from the recent seed financing will be used to advance ASX-100 into first-in-human clinical trials. The company is led by president and CEO Marc Appel and is advancing drug-development programs across multiple disease areas driven by dysregulated immune signaling.

• Ocuphire Pharma

  Participated · Equity · Jul 2019

  Ocuphire's lead product is Nyxol, a preservative-free ophthalmic formulation of phentolamine mesylate being developed as a once-daily eye drop for night vision disturbances (NVD), glaucoma, reversal of mydriasis and a fixed-dose combo for presbyopia. Nyxol has safety and efficacy data from five Phase 1 and Phase 2 trials and has demonstrated moderately reduced pupil size, significant intraocular pressure lowering, and convenient once-daily dosing. The company is enrolling double-masked, randomized, placebo-controlled Phase 2 trials in glaucoma (ORION-1) and reversal of mydriasis (MIRA-1), and is preparing a Phase 3 study in NVD (LYNX-1). Clinical results from ORION-1 and MIRA-1 are expected later this year; as of mid-July the company had enrolled more than 50% of the 40 patients in ORION-1. Ocuphire has built management, board, clinical and manufacturing partners, and a medical advisory board of ophthalmic KOLs to support development and commercialization. Proceeds from recent financing will be used to fund multiple late Phase 2 clinical trials of Nyxol.

No current team members are available.